Recently public Acorda Therapeutics (ACOR) is on a mission to restore neural function in people with demyelinating conditions. With one drug already on the market and another one in late stage clinical trials, Acorda is well positioned to make some waves in multiple sclerosis, spinal cord injury, and related disorders…
